This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Veronique Sans, MD; Thomas Jouary, MD; Thomas Hubiche, MD; Denis Smith, MD; Brigitte Milpied, MD; Alain Taieb, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Epidermal growth factor receptor (EGFR) inhibitors are usually well-tolerated, novel molecules that are indicated to treat advanced carcinomas. We report herein a case of an unusual rash occurring during cetuximab treatment.

Report of a Case

A 71-year-old man presented with a history of colon cancer with liver involvement in August 2005. After 10 courses of FOLFIRI chemotherapy (leucovorin calcium [folinic acid], fluorouracil, and irinotecan hydrochloride), an intestinal resection was performed in January 2006, followed by 6 additional courses of FOLFIRI. Liver metastases were increasing in June 2006, so cetuximab was added to the regimen at an initial dose of 400 mg/m². An urticarial rash with facial angioedema and severe hypotension occurred within the first 2 hours of cetuximab treatment. H₁ receptor antagonists were introduced, and cetuximab treatment was decreased to 250 mg/m² per infusion with . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION